Literature DB >> 23791882

DYRK2 controls the epithelial-mesenchymal transition in breast cancer by degrading Snail.

Rei Mimoto1, Naoe Taira, Hiroyuki Takahashi, Tomoko Yamaguchi, Masataka Okabe, Ken Uchida, Yoshio Miki, Kiyotsugu Yoshida.   

Abstract

The epithelial-mesenchymal transition (EMT) plays a fundamental role in the early stages of breast cancer invasion. Snail, a zinc finger transcriptional repressor, is an important regulator of EMT. Snail is phosphorylated by GSK3β and is subsequently degraded by βTrCP-mediated ubiquitination. We identified an additional kinase, DYRK2, that regulates Snail stability. Knockdown of DYRK2 promoted EMT and cancer invasion in vitro and in vivo. Consistent with these results, DYRK2 was found to be down-regulated in human breast cancer tissue. Patients with low DYRK2-expressing tumors had a worse outcome than those with high DYRK2-expressing tumors. These findings revealed that DYRK2 regulates cancer invasion and metastasis by degrading Snail.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Breast cancer; DYRK2; E-cadherin; EMT; Snail

Mesh:

Substances:

Year:  2013        PMID: 23791882     DOI: 10.1016/j.canlet.2013.06.005

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  32 in total

Review 1.  Regulation of the protein stability of EMT transcription factors.

Authors:  V M Díaz; R Viñas-Castells; A García de Herreros
Journal:  Cell Adh Migr       Date:  2014       Impact factor: 3.405

2.  Downregulation of DYRK2 can be a predictor of recurrence in early stage breast cancer.

Authors:  Yasuko Enomoto; Shin-ichi Yamashita; Yasuteru Yoshinaga; Yasuyoshi Fukami; So Miyahara; Kazuki Nabeshima; Akinori Iwasaki
Journal:  Tumour Biol       Date:  2014-08-06

3.  DYRK2 regulates epithelial-mesenchymal-transition and chemosensitivity through Snail degradation in ovarian serous adenocarcinoma.

Authors:  Noriko Yamaguchi; Rei Mimoto; Nozomu Yanaihara; Yoshimi Imawari; Shinichi Hirooka; Aikou Okamoto; Kiyotsugu Yoshida
Journal:  Tumour Biol       Date:  2015-02-25

4.  Impairment of DYRK2 augments stem-like traits by promoting KLF4 expression in breast cancer.

Authors:  R Mimoto; Y Imawari; S Hirooka; H Takeyama; K Yoshida
Journal:  Oncogene       Date:  2016-10-10       Impact factor: 9.867

Review 5.  Engagement of DYRK2 in proper control for cell division.

Authors:  Naoe Taira Nihira; Kiyotsugu Yoshida
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

6.  Overexpression of histone demethylase JMJD5 promotes metastasis and indicates a poor prognosis in breast cancer.

Authors:  Zhihua Zhao; Chuntao Sun; Fengqi Li; Jiankui Han; Xanjun Li; Zhenguo Song
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

7.  Regulation of Glioma Cells Migration by DYRK2.

Authors:  Yifen Shen; Li Zhang; Donglin Wang; Yifeng Bao; Chao Liu; Zhiwei Xu; Wei Huang; Chun Cheng
Journal:  Neurochem Res       Date:  2017-07-04       Impact factor: 3.996

8.  Induction of amphiregulin by p53 promotes apoptosis via control of microRNA biogenesis in response to DNA damage.

Authors:  Naoe Taira; Tomoko Yamaguchi; Junko Kimura; Zheng-Guang Lu; Shinji Fukuda; Shigeki Higashiyama; Masaya Ono; Kiyotsugu Yoshida
Journal:  Proc Natl Acad Sci U S A       Date:  2013-12-30       Impact factor: 11.205

Review 9.  The network of pluripotency, epithelial-mesenchymal transition, and prognosis of breast cancer.

Authors:  Ioannis A Voutsadakis
Journal:  Breast Cancer (Dove Med Press)       Date:  2015-09-07

10.  DYRK2 Negatively Regulates Type I Interferon Induction by Promoting TBK1 Degradation via Ser527 Phosphorylation.

Authors:  Tai An; Shu Li; Wei Pan; Po Tien; Bo Zhong; Hong-Bing Shu; Shuwen Wu
Journal:  PLoS Pathog       Date:  2015-09-25       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.